Cody, everything you say is accurate, but there are at least two factors that change the landscape. The first is time. Some may dispute it, but I believe we are now 12 months into the COVID pandemic. Anecdotally, I saw family and friends with severe, mysterious illnesses last December. Much has been accomplished in a year with the first patient being vaccinated today. However, one size will not fit all. Much research is still required and the most optimistic outcome is herd mentality by summer 2021.

Second is the numbers. The number of countries impacted. The number of deaths. The number of cases. The number of hospital beds. The number of ICU wards at or near capacity. If NGIO works diligently, it will have an opportunity to make an impact. Much of the data EvH has compiled over the past 20 years may be proprietary and only available to Generex.

It is a long shot, but do we (as investors) truly know what we have in Ii-key? I am interested in finding out. If, and it's a big if, NGIO is busy working on a multi-virus platform and/or treatment and mitigation, we may just have something at the end of the road. We're waiting to see those river cards.